$319 Million is the total value of Krensavage Asset Management, LLC's 13 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 15.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ENTA | Sell | ENANTA PHARMACEUTICALS INC | $53,218,000 | +28.7% | 936,777 | -0.3% | 16.69% | +18.9% |
| ALKS | Sell | ALKERMES PLC | $44,470,000 | +7.4% | 1,441,967 | -14.6% | 13.95% | -0.8% |
| REGN | Sell | REGENERON PHARMACEUTICALS | $44,265,000 | -3.5% | 73,143 | -10.9% | 13.89% | -10.8% |
| UTHR | Sell | UNITED THERAPEUTICS CORP | $38,261,000 | -2.9% | 207,287 | -5.6% | 12.00% | -10.3% |
| TARO | Buy | TARO PHARMACEUTICAL INDUS | $34,715,000 | -11.3% | 545,583 | +0.3% | 10.89% | -18.0% |
| MCK | Sell | MCKESSON CORP | $32,816,000 | +3.1% | 164,591 | -1.1% | 10.29% | -4.7% |
| BIIB | Buy | BIOGEN INC | $29,205,000 | -13.5% | 103,202 | +5.8% | 9.16% | -20.1% |
| EXEL | New | EXELIXIS INC | $21,140,000 | – | 1,000,000 | +100.0% | 6.63% | – |
| SRGA | Sell | SURGALIGN HOLDINGS INC | $6,903,000 | -22.4% | 6,332,945 | -1.1% | 2.16% | -28.4% |
| EGRX | Buy | EAGLE PHARMACEUTICALS INC | $6,012,000 | +98.4% | 107,773 | +52.2% | 1.89% | +83.3% |
| IVC | Sell | INVACARE CORP | $4,242,000 | -41.7% | 891,259 | -1.2% | 1.33% | -46.1% |
| TVTX | Sell | TRAVERE THERAPEUTICS INC | $3,327,000 | +62.8% | 137,203 | -2.0% | 1.04% | +50.4% |
| NXTC | Sell | NEXTCURE INC | $208,000 | -17.5% | 30,927 | -1.4% | 0.06% | -24.4% |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -10,890 | -100.0% | -0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP | 36 | Q3 2023 | 18.1% |
| Enanta Pharmceuticals Inc | 35 | Q3 2023 | 16.7% |
| INVACARE CORP | 28 | Q3 2021 | 5.8% |
| RTI SURGICAL INC | 23 | Q2 2020 | 7.9% |
| MCKESSON CORP | 20 | Q3 2022 | 16.3% |
| BIOGEN INC | 19 | Q3 2023 | 16.0% |
| MERCK & CO. INC. | 18 | Q1 2019 | 11.1% |
| DIGIRAD CORP | 18 | Q1 2019 | 1.0% |
| REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 16.1% |
| ALKERMES PLC | 16 | Q3 2023 | 14.1% |
View Krensavage Asset Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| SURGALIGN HOLDINGS, INC. | February 19, 2021 | 5,380,449 | 6.6% |
| RTI SURGICAL, INC. | February 14, 2019 | 3,852,567 | 6.1% |
| Aviragen Therapeutics, Inc. | February 15, 2018 | 2,292,058 | 5.9% |
| ENANTA PHARMACEUTICALS INC | February 15, 2017 | 883,902 | 4.6% |
| Biota Pharmaceuticals, Inc. | February 17, 2016 | 2,267,655 | 5.9% |
View Krensavage Asset Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SCHEDULE 13G | 2024-02-27 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-15 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-16 |
| 13F-HR | 2023-02-15 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-17 |
| 13F-HR | 2022-02-15 |
View Krensavage Asset Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.